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Corticosteroid switch after progression on abiraterone acetate 
plus prednisone 
 
Giandomenico Roviello1 · Navid Sobhani2,3 · Silvia Paola Corona2 · Alberto D’Angelo4 
 
 
 
Abstract 
Introduction Abiraterone acetate plus prednisone is approved in metastatic castration-resistant prostate cancer. There is some 
evidence in favour of the steroid switch from prednisone to dexamethasone in patients who progressed whilst on abiraterone 
acetate plus prednisone or prednisolone. 
Materials and Methods The aim of this review is to discuss the results from the clinical studies available, examining potential 
mechanisms of action and patient selection criteria for this treatment option. 
Results A total of four studies were evaluated. Among possible eligibility criteria for steroid switch, we found: PSA progres- 
sion without any radiological or clinical progression during abiraterone acetate + prednisone; no high-grade adverse events 
related to CYP-17 inhibition; and unfitness for chemotherapy or radium-223. 
Conclusion  Although large randomized prospective trials are warranted, steroid switch seems to off a good option for 
certain patients treated with abiraterone acetate plus prednisone or prednisolone. 
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Introduction 
 
Prostate cancer is one of the most common causes of can- 
cer-related death in the western world [1]. In recent years, 
therapeutic management of prostate cancer has significantly 
changed for both metastatic and non-metastatic castration- 
resistant prostate cancer (CRPC), as well as for hormonal- 
naive patients [2]. Since 2010, five novel drugs with differ- 
ent mechanisms of action have shown to increase survival 
[2]. However, no agent is curative and inevitably all treated 
patients will evolve into disease progression. 
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Abiraterone acetate (AA) is a CYP17 inhibitor which 
blocks the synthesis of androgens. CYP17 catalyzes the 
conversion of pregnenolone and progesterone to testoster- 
one precursors, dehydroepiandrosterone and androstenedi- 
one. Since CYP17 impacts the production of glucocorti- 
coids, the levels of cortisol fall, and the organism produces 
adrenocorticotropic hormone (ACTH) as a compensatory 
strategy. This induces an increase in the mineralocorticoid 
levels, even if aldosterone itself is suppressed. The rise in 
ACTH can be hampered with the concomitant administra- 
tion of steroids. Thus, AA is administered in combination 
with prednisone or prednisolone 5 mg twice daily [3, 4] to 
prevent the secondary mineralocorticoid excess related to 
the blockade of CYP17 [5]. However, prednisone or predni- 
solone are not the only concomitant steroids added to AA. 
Some clinical trials have investigated the combination of 
dexamethasone with AAand reported clinical effi [6]. 
Based on these results, diff ent studies have investigated 
the possibility of a ‘steroid switch’ (SS) from prednisone to 
dexamethasone in patients who progress on AA plus pred- 
nisone or prednisolone. The aim of this review is to report on 
the currently available data on the topic, examining potential 
scenarios for the corticosteroid switch. 
 
 
 
Role of abiraterone acetate in CRPC 
 
Abiraterone acetate has been the fi t hormonal agent to 
improve the survival of patients with metastatic CRPC 
[3]. Two phase III, multinational, double-blind, rand- 
omized, placebo-controlled trials established the effi 
and safety of the combination of AA with prednisone in 
metastatic CRPC [3, 4]. The fi t study, COU-AA-301, 
involved patients who previously received docetaxel, 
while the second study, COU-AA-302, involved only 
patients who had not received any chemotherapy previ- 
ously and did not have clinically signifi cancer-related 
symptoms (i.e., asymptomatic or minimally symptomatic 
patients). Both studies enrolled a large number of patients 
(more than 1000) and had overall survival as the pri- 
mary endpoint (co-primary in COU-AA-302). Secondary 
endpoints included toxicity and diff ent events related 
to the progression of the disease. The fi analysis of 
COU-AA-301 estimated 4.6 months improvement in over- 
all survival (15.8 months for AA versus 11.2 months for 
prednisone + placebo) [7] while the COU-AA-302 con- 
fi med also an improvement in survival (4.4 months with 
34.7 months for AA versus 30.3 in the placebo group, 
respectively) [8]. In addition, all secondary end-points 
were in favour of the combination of AA with pred- 
nisone compared to placebo with prednisone. Finally, 
COU-AA-301 and COU-AA-302 confi med the higher 
incidence of adverse events associated with mineralocor- 
ticoid activity with AA plus prednisone in comparison to 
prednisone alone [9]. A signifi increasing of all-grade 
hypertension (risk ratio (RR) = 1.53), cardiac disorders 
(RR = 1.47), liver function test abnormalities (RR = 1.93), 
hypokalaemia (RR = 1.56), grade ≥ 3 adverse events, car- 
diac disorders (RR = 1.55) and hypokalaemia (RR = 4.23) 
has been observed in favour the CYP-17 inhibitors com- 
pared to compared with placebo. Based on these studies, 
the combination of AA with prednisone is approved for the 
treatment of patients with metastatic CRPC. 
 
 
The basis for the “steroid switch” 
 
During AA-based therapy, inhibition of androgen synthesis 
is achieved by blocking the CYP17, key enzyme responsible 
for adrenal and intratumoral androgen synthesis from preg- 
nenolone. In addition, a corticosteroid drug must be admin- 
istered during treatment to avoid side effects. Corticosteroids 
have been widely used in CRPC. Their antitumour eff 
is assumed to be due to the reduction in the synthesis of 
adrenal androgens via ACTH production suppression [10, 
11]. For this reason, all corticosteroids, including hydrocor- 
tisone, prednisolone and dexamethasone were thought to be 
equally effective [11]. Even though numerous explanations 
have been proposed, the exact mechanism for the SS effect 
is still poorly understood (Fig. 1). 
 
 
 
 
Fig. 1  Pathway that are involved in the ‘steroid switch’: GR glucocorticoid receptor, TGF transforming growth factor, MR mineralocorticoid 
receptor, VEGF vascular endothelial growth factor, HGF hepatocyte growth factor, IL interleukin, AR androgen receptor 
 
 
 
 
 
Different glucocorticoid receptor (GR) activation between 
prednisolone and dexamethasone may explain the SS effect. 
Patients affected by prostate cancer who underwent andro- 
gen deprivation therapy showed a significant increase in GR 
expression [12]. Androgen receptor (AR) and GR belong 
both to the nuclear steroid receptor family and have similar 
structure and function, also sharing some of their transcrip- 
tional targets [12, 13]. Several hypotheses on AR and GR 
receptor interaction have been presented. AR inhibition acti- 
vates GR, which binds to the nuclear androgen response ele- 
ments and controls AR target genes, thereby bypassing the 
AR pathway [12, 13]. With the progression of CRPC over 
time, prednisolone can increasingly turn on the GR receptor 
and this effect could be reversed by switching to dexametha- 
sone, which happens to have decreased affinity for GR. 
Differences in mineralocorticoid receptor (MR) activa- 
tion between prednisolone and dexamethasone might also 
aff  effi   , even though only few studies have investi- 
gated the role of MRs in CRPC [14]. The glucocorticoid 
resistance which takes place once MR is activated might be 
counteracted with a ‘SS’ to dexamethasone, which has less 
affi for MR receptor [14]. MR is expressed in prostate 
tumour cells independent of AR and seems to be controlled 
by inflammatory cytokines, which in turn are involved with 
prostate cancer progression [15]. Changes in MR expres- 
sion, as a result of inflammatory cytokines, are thought to be 
implicated in prostate cancer carcinogenesis [16]. 
It is also possible that corticosteroid-responsive AR muta- 
tions, activated by prednisolone but not dexamethasone, may 
be responsible for the occurring resistance. It is speculated 
that the effect of ligands other than testosterone might be a 
result of AR mutations in the hinge and/or ligand-binding 
domain [17]. Some studies have reported AR mutations trig- 
gered by corticosteroids, dexamethasone and prednisolone 
included [18, 19]. 
Acting on the modulation of cellular growth factors, 
cytokines and transcription factors, which might also lead 
to differences in the activity against the tumour, glucocor- 
ticoids play an anti-inflammatory and anti-angiogenic role 
in prostate cancer [20, 21]. Dexamethasone elicits an anti- 
angiogenic effect on prostate cancer, by lowering the expres- 
sion of vascular endothelial growth factor, IL-6 and IL-8, via 
activation of the GR-mediated pathway [22, 23]. IL-6 has 
been shown to stimulate prostate tumour cells replication via 
GR in an androgen-independent way and to activate the AR 
via STAT3-dependent signalling [24]. Moreover, modifica- 
tions in IL-6 serum levels correlated with dexamethasone in 
CRPC patients [25]. 
Finally, differences in pharmacokinetics between predni- 
solone and dexamethasone have been observed. Dexametha- 
sone might cause a stronger ACTH suppression due to its 
longer half-life and a more efficient activity against cancer 
than prednisolone [26]. Dexamethasone might reduce min- 
eralocorticoid activity while exerting a more potent gluco- 
corticoid activity than prednisone [27]. 
 
 
Clinical experience of SS 
 
To date, only few studies showed the efficacy of SS in CRPC 
(Table 1) [28–31]; all studies involved patients with meta- 
static CRPC who progressed after AA + prednisone and 
 
 
Table 1  Patients characteristics of included studies 
 
Study author Nature Previous lines Num- Median age % % Gleason % Patients Median serum PSA 
  of treatment berof (range) ECOG score ≥ 8 with visceral (µg/l or ng/ml) 
   patients  (0–1)  metastasis  
Lorente et al. 
(2014) 
Retrospective Chemotherapy 30 68.9 (NR) 90 NR 3.3* 199.5 (9.7–2689) 
Fenioux et al. Retrospective 7 patients 48 82.33 (56.47– 73 62.5*** 4.1 42.85 (5.20–1 275) 
2018 
 
Romero- 
Laorden et al. 
SWITCH 
 
 
Phase II 
prospective 
study 
received 
docetaxel 
1 median num- 
ber of prior 
treatment lines 
94.00) 
 
26 73.0 (60–85) 96 54 15 36.1 (4.46–965.2) 
 
88 (4–1550) 
 
 
 
 
NR not reported, CRPC castration resistant prostate cancer 
*Patients with bone and visceral metastasis 
**7 Patients received docetaxel 
***Gleason > = 7 
(2018) for CRPC  
Roviello et al. Retrospective   3 median num- 36 76 (62–85) 83 47 25 
(2018) ber of prior 
treatment lines 
for CRPC 
 
 
 
 
Table 2  Efficacy of steroid switch  
Study author Median duration of 
previous AA + P 
Time to PSA pro- 
gression median 
PFS median OS median Best PSA response (%) 
Lorente et al. (2014) 6.3 months 11.7 weeks NR NR ≥ 50% (20) 
Fenioux et al. (2018) 8.9 months 10.35 months NR NR ≥ 50% (48) 
Romero-Laorden et al. (2018) 5.8 months NR 11.8 months 20.9 months ≥ 50% (35) 
Roviello et al. (2018) 2.4 months* NR 10.8 Weeks 17.6 Weeks ≥ 50% (11) 
NR not reported      
*Reported as 9.9 weeks      
 
switched to AA + Dexamethasone. The results of the four 
studies are summarized below and in Tables 1 and 2. 
Preliminary data on SS date back to the 2014 retrospec- 
tive study performed by Lorente et al. [28] where 30 patients 
affected by CRPC switched from twice daily 5 mg of pred- 
nisone/prednisolone to once daily 0.5–1 mg of dexametha- 
sone after PSA progression. The progression of PSA was cat- 
egorized as an increase of 25% over the nadir and confirmed 
by an additional read after 3 weeks at the earliest. The first 
AA in combination with prednisone/prednisolone was given 
for 27.7 weeks average time to patients (95% CI 11.7–124.4) 
whereas the following AA + dexamethasone was adminis- 
tered for 20.6 weeks of average time (95% CI 16.2–24.9). 
Six patients (20%) achieved a confirmed PSA decrease 
of > 50% while 11 patients (39%) reached a satisfactory PSA 
decrease of ≥ 30%. The average time to PSA progression was 
11.7 weeks (95% CI 8.6–14.8) in the total cohort adminis- 
tered with AA + dexamethasone, and 27.6 weeks (95% CI 
14.5–40.7) in patients with a confirmed decreased of PSA 
value of at least 50%. According to RECIST criteria, fi e 
patients accomplished a stable disease state and two patients 
reported a partial response. Although one patient returned to 
prednisolone due to a grade 2 hypotension, no grade 3 and 
grade 4 adverse events were reported, and the therapy was 
well tolerated. 
In 2018, Fenioux et al. reported the data of a retrospective 
analysis on patients with metastatic CRPC who switched 
from AA + prednisone10mg daily to AA + dexamethasone 
(0.5 mg daily) after PSA progression without any radiologi- 
cal or clinical sign of disease [29]. A total of 48 patients 
underwent SS. A median progression-free survival of 
10.35 months (95% CI 4.83–15.21) was observed after SS. 
Thirteen (48.15%) patients had a PSA response. Based on 
the multivariate Cox analysis, the authors established a prog- 
nostic model, identifying 3 levels of risk (low, intermediate 
and high), defined by PSA level at the time of SS and hor- 
mone sensitivity. Treatment with AA + dexamethasone was 
well tolerated with no grade 3 or 4 toxicity reported after SS. 
The SWITCH study (NCT02928432) was a prospective 
multicenter study conducted at four university hospitals in 
Spain. This was the first prospective study reporting data 
on SS [30]. This study enrolled patients who progressed on 
AA + prednisone (biochemical progression or limited radio- 
logical progression). The primary endpoint was measured as 
the proportion of patients achieving a PSA decline of ≥ 30%. 
A total of 26 metastatic CRPC patients were enrolled. All 
patients had PSA progression and 12 (46.2%), also pre- 
sented a limited radiological progression as defi in the 
study inclusion criteria. A decline of PSA > 30% and > 50% 
was observed in 12 (46.2%) and 8 (35%) of the enrolled 
patients, respectively. Median PSA progression from SS 
was 5.3 months (95% CI 3.1–7.5) and a moderate but sig- 
nifi      correlation was observed with the prior response 
to AA + prednisone (p = 0.001). Two radiological responses 
were observed. The median time to radiographic progression 
after the SS was 11.8 months (95% CI 6.6–17.1) and over- 
all survival was 20.9 months (95%CI 10.0–31.7). No grade 
3–4 related adverse events were reported. Interestingly, the 
authors performed a biomarker study showing that patients 
with normal status androgen receptor in circulating tumour 
DNA respond to SS. 
The safety and activity of SS in patients affected by 
advanced, pre-treated CRPC who progressed after AA treat- 
ment, was assessed by a further retrospective and small study 
in 2018 [31]. Thirty-six patients were administered with oral 
daily AA + 0.5 mg dexamethasone until unacceptable tox- 
icity or disease progression. The study reported a median 
progression-free survival of 10.8 weeks (95% CI 9.2–16), 
a median survival of 17.6 weeks (95% CI 15.8–28.8) and 
a ≥ 50% decrease of PSA in 4 patients (4%) albeit greater 
survival and effi has been shown for the subgroup of 
patients treated for more than 3 months with AA. No grade 
3 and 4 adverse events were reported, and the therapy was 
well tolerated. 
Finally, data from a randomised phase II trial compared 
the efficacy of prednisone at the standard dose and dexa- 
methasone in chemotherapy-naïve patients with CRPC [12]. 
The study showed that 7 of the 19 (37%) evaluable cases 
had a confi med PSA response to dexamethasone when a 
crossover from prednisone to dexamethasone was performed 
at PSA progression. 
 
 
 
 Table 3  Eligibility criteria for 
SS in metastatic CRPC patients 
Main
 
PSA progression without any radiological or clinical progression during Abiraterone acetate + prednisone 
No adverse events of related to resistant CYP-17 inhibition 
Patients unfit for chemotherapy or Radium-223 
Secondary 
> 50% PSA response to prior abiraterone acetate + prednisone 
Limited radiological progression 
≤ 3 new asymptomatic metastasis in bone scan, 
No new soft tissue lesions, 
< 40% increase in the size of target lesions according to RECIST criteria 
Short time to PSA progression (<6 months) 
 
 
 
Better patient selection 
 
Abiraterone acetate has been the fi t hormonal agent to 
achieve a survival benefit in metastatic CRPC patients. The 
SS off  the opportunity to prolong the treatment with 
AA in a non-expensive, safe fashion. However, there is a 
need for better identifi of the patients who 
may benefit from SS. To date, all published studies, except 
from 2, evaluated patients with PSA progression without 
any radiological or clinical progression [30, 31]. Therefore, 
in the absence of specific guidelines, it seems that the best 
candidate to a SS during AA + prednisone is the patient with 
PSA progression alone, while the role of SS in patients with 
limited radiological progression is still unclear. 
Another important issue is to identify patients who may 
benefi  from SS in relation to the duration and effi  of 
prior AA+ prednisone. Although one study appears to dem- 
onstrate that short time to PSA progression (<6 months) 
on AA + prednisone is a positive prognostic factor during 
subsequent SS [29], the SWITCH study reported a correla- 
tion between biochemical PFS on AA + dexamethasone and 
biochemical PFS on AA + prednisone. In addition, the per- 
centage of PSA response during SS was 41.7% and 21.4%, 
respectively, in patients with or without previous PSA 
response on AA + prednisone [30]. In line with these data, 
another study showed that the efficacy and survival during 
SS correlated with prior AA duration [31]. However, more 
data is needed to understand the role of prior AA + pred- 
nisone as a prognostic factor during SS. 
Other possible favourable prognostic factors are the long 
duration of response to hormone therapy (>5 years) and 
low PSA level (<50 ng/mL) at the time of SS [29]. Finally, 
the prior use of docetaxel does not appear to correlate with 
radiographic PFS [29]. 
Furthermore, there is the important question of what 
therapy to administer after SS. In this context, only two stud- 
ies reported data on overall survival, and on this basis, it 
appears that either chemotherapy or radium-223 (if possible) 
is the best approaches in patients who progressed after SS. 
However, both safety and efficacy of these drugs after a pro- 
gression of disease on a prior treatment of AA + prednisone 
and subsequent SS are still to be defined. Table 3 reports 
possible eligibility criteria for SS. 
Only one study  performed  biomolecular  analysis 
to identify possible predictive factors [30]. It has been 
reported that biochemical PFS, PSA response and radio- 
graphic PFS are lower in patients with androgen receptor 
mutations [30]. It must be noted that such type of therapy 
is most eff    e in those patients whose androgen recep- 
tor is not mutated nor alternatively spliced. One of the 
most common features of CRPC is a splice version of the 
androgen receptor (AR-V7), which constitutively activates 
 
 
 
 
 
Fig. 2  Possible study consort diagram. *Including patients without any radiological or clinical progression; patients with no high grade adverse 
events related to CYP-17 inhibition. AA Abiraterone acetate, P prednisone, D dexamethasone 
 
 
 
the receptor, therefore bypassing the need for androgens 
and invalidating any androgen deprivation approach [33]. 
It is common practice to maintain therapy with novel 
hormonal agent beyond PSA rise, until radiological and/ 
or clinical progression of the disease [34]. For this rea- 
son, the SS may be an optimal and much less expensive 
strategy in patients who had a PSA progression during 
AA + prednisone. In addition, the SS may be a good option 
for patients unfi  for chemotherapy and not eligible for 
Radium-223, as its effi and duration of response are 
comparable to those of enzalutamide after AA in CRPC 
treatment [35]. Unfortunately, all except for one of the 
studies reported in our review, are retrospective, with 
incomplete information and small sample sizes (a total of 
146 patients). The data, therefore, cannot be considered 
conclusive. Large randomised prospective trials are war- 
ranted to determine the usefulness and the impact on sur- 
vival of SS in CRPC patients with PSA progression during 
AA + prednisone. An example of design for a possible trial 
is reported in Fig. 2. Based from the assumption that SS 
might be recommended to patients treated with AA + pred- 
nisone without any radiological or clinical progression, 
the study should investigate the SS in men treated with 
AA + prednisone who perform PSA progression without 
any radiological or clinical progression and with no high- 
grade adverse events related to CYP-17 inhibition. After 
PSA progression, patients should be randomized to receive 
AA + dexamethasone or continue AA + prednisone until 
the further PSA progression or radiological or clinical pro- 
gression of disease. In conclusion, best sequence of treat- 
ment in CRPC is still unclear [36, 37], SS seems to off a 
good option for certain patients treated with AA + P. 
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